A study in Science Translational Medicine reports that suppressing microRNA-224 (miR-224) can prevent decline in heart function in mouse models of pulmonary arterial hypertension. Researchers used lung-directed antisense inhibition and an AAV1 gene therapy to inhibit miR-224, showing that dampening the microRNA reduced the pathological drivers tied to pulmonary artery smooth muscle cell expansion. The work positions miR-224 as an actionable target for a disease-modifying strategy rather than purely vasodilatory treatment. It also underscores the potential for nucleic acid therapeutics delivered to the lung to alter disease mechanisms at the tissue level. For biotech, it adds momentum to microRNA therapeutics in cardiopulmonary disease and supports the rationale for advancing RNA-target programs toward translational studies.